Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIGG: Intra-nodal gentamicin for suppurated cat scratch disease lymphadenitis
2024-512037-32-00Phase 3Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2024
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised trial of gentamicin in bartonellosis and cat scratch disease (CSD) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Favorable outcome of cat scratch disease adenitis at day 28. Started Sep 2024; status: completed.
02
Drugs
gentamicin
03
Conditions
bartonellosiscat scratch disease (CSD)
Beyond the preview
Go deeper on 2024-512037-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512037-32-00.